SOUTH SAN FRANCISCO, Calif.,
July 27, 2021 /PRNewswire/
-- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today
announced that it will report its second quarter 2021 financial
results after market close on Tuesday,
August 3, 2021. Rigel senior management will follow
the announcement with a live conference call and webcast at
4:30pm Eastern Time (1:30pm Pacific Time) to discuss the financial
results and give an update on the business.
Participants can access the live conference call by dialing
877-407-3088 (domestic) or 201-389-0927 (international). The
conference call and accompanying slides will also be webcast live
and can be accessed from the Investor Relations section of the
company's website at www.rigel.com. The webcast will be
archived and available for replay for 90 days after the call via
the Rigel website.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals,
Inc., is a biotechnology company dedicated to discovering,
developing, and providing novel small molecule drugs that
significantly improve the lives of patients with hematologic
disorders, cancer and rare immune diseases. Rigel's pioneering
research focuses on signaling pathways that are critical to disease
mechanisms. The company's first FDA approved product is
TAVALISSE® (fostamatinib disodium hexahydrate) tablets,
the only oral spleen tyrosine kinase (SYK) inhibitor for the
treatment of adult patients with chronic immune thrombocytopenia
who have had an insufficient response to a previous treatment. The
product is also commercially available in Europe (TAVLESSE) and Canada (TAVALISSE) for the treatment of
chronic immune thrombocytopenia in adult patients.
Fostamatinib is currently being studied in a Phase 3 clinical
trial (NCT03764618) for the treatment of warm autoimmune hemolytic
anemia (wAIHA)1; a Phase 3 clinical trial (NCT04629703)
for the treatment of hospitalized high-risk patients with
mild-to-moderate COVID-191; an NIH/NHLBI-sponsored Phase
3 clinical trial for the treatment of COVID-19 in hospitalized
patients on oxygen therapy, and a Phase 2 clinical trial for the
treatment of COVID-19 being conducted by Imperial College London.
An NIH/NHLBI-sponsored Phase 2 clinical trial for the treatment of
hospitalized patients with COVID-19, in collaboration with Inova
Health System, was recently completed.
Rigel's other clinical programs include its interleukin
receptor-associated kinase (IRAK) inhibitor program, and a
receptor-interacting serine/threonine-protein kinase (RIP1)
inhibitor program in clinical development with partner Eli Lilly
and Company. In addition, Rigel has product candidates in
development with partners AstraZeneca, BerGenBio ASA, and Daiichi
Sankyo.
For further information, visit www.rigel.com or follow
us on Twitter or LinkedIn.
Please see www.TAVALISSE.com for the full Prescribing
Information.
1The product for this use or indication is
investigational and has not been proven safe or effective by any
regulatory authority.
Investor Contact:
Jodi Sievers
Rigel Pharmaceuticals, Inc.
Phone: 650.624.1232
Email: ir@rigel.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2021-financial-results-and-business-update-301341693.html
SOURCE Rigel Pharmaceuticals, Inc.